JP2007522235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522235A5 JP2007522235A5 JP2006553265A JP2006553265A JP2007522235A5 JP 2007522235 A5 JP2007522235 A5 JP 2007522235A5 JP 2006553265 A JP2006553265 A JP 2006553265A JP 2006553265 A JP2006553265 A JP 2006553265A JP 2007522235 A5 JP2007522235 A5 JP 2007522235A5
- Authority
- JP
- Japan
- Prior art keywords
- piperazinyl
- pyrimidinyl
- oxy
- ethyl
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 36
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- VNXORXQSQPSJIS-MRXNPFEDSA-N 3-amino-5-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1-methylquinoxalin-2-one Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(N)C(=O)N(C)C=4C=CC=3)C=2)C)=CC=C(F)C=C1 VNXORXQSQPSJIS-MRXNPFEDSA-N 0.000 claims 2
- HHUFEEWQDCKYHP-CQSZACIVSA-N 3-amino-7-fluoro-5-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-quinoxalin-2-one Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(N)C(=O)NC=4C=C(F)C=3)C=2)C)=CC=C(F)C=C1 HHUFEEWQDCKYHP-CQSZACIVSA-N 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- RQXICNWXPUNLIY-SJORKVTESA-N n-[4-[6-[(2r)-4-[(1s)-1-(4-fluorophenyl)ethyl]-2-methylpiperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide Chemical compound C1([C@@H](N2C[C@@H](C)N(CC2)C=2N=CN=C(OC=3C=4N=C(NC(C)=O)SC=4C=CC=3)C=2)C)=CC=C(F)C=C1 RQXICNWXPUNLIY-SJORKVTESA-N 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- -1 (4-fluorophenyl) ethyl Chemical group 0.000 claims 1
- RFNPVIDUEFCNBW-SFHVURJKSA-N 2-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3N=C4C=CC=CC4=CC=3)C=2)C)=CC=C(F)C=C1 RFNPVIDUEFCNBW-SFHVURJKSA-N 0.000 claims 1
- OWIKVEWTUZUYMI-KRWDZBQOSA-N 2-chloro-8-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=NC(Cl)=CC=C4C=CC=3)C=2)C)=CC=C(F)C=C1 OWIKVEWTUZUYMI-KRWDZBQOSA-N 0.000 claims 1
- GLMDIKWDRSTZQS-SFHVURJKSA-N 3-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyisoquinoline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3N=CC4=CC=CC=C4C=3)C=2)C)=CC=C(F)C=C1 GLMDIKWDRSTZQS-SFHVURJKSA-N 0.000 claims 1
- MVZKZBQIIRXRSG-OAHLLOKOSA-N 3-amino-5-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-quinoxalin-2-one Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(N)C(=O)NC=4C=CC=3)C=2)C)=CC=C(F)C=C1 MVZKZBQIIRXRSG-OAHLLOKOSA-N 0.000 claims 1
- VNXORXQSQPSJIS-INIZCTEOSA-N 3-amino-5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1-methylquinoxalin-2-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(N)C(=O)N(C)C=4C=CC=3)C=2)C)=CC=C(F)C=C1 VNXORXQSQPSJIS-INIZCTEOSA-N 0.000 claims 1
- MVZKZBQIIRXRSG-HNNXBMFYSA-N 3-amino-5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-quinoxalin-2-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(N)C(=O)NC=4C=CC=3)C=2)C)=CC=C(F)C=C1 MVZKZBQIIRXRSG-HNNXBMFYSA-N 0.000 claims 1
- HHUFEEWQDCKYHP-AWEZNQCLSA-N 3-amino-7-fluoro-5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-quinoxalin-2-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(N)C(=O)NC=4C=C(F)C=3)C=2)C)=CC=C(F)C=C1 HHUFEEWQDCKYHP-AWEZNQCLSA-N 0.000 claims 1
- WUGMTSHNAYJGRG-UHFFFAOYSA-N 4-(2,3-dihydro-1,4-benzodioxin-5-yloxy)-6-[4-[1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidine Chemical compound C1CN(C=2N=CN=C(OC=3C=4OCCOC=4C=CC=3)C=2)CCN1C(C)C1=CC=C(F)C=C1 WUGMTSHNAYJGRG-UHFFFAOYSA-N 0.000 claims 1
- JSCPTIXCTAHXPN-KRWDZBQOSA-N 4-(2,3-dihydro-1,4-benzodioxin-6-yloxy)-6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidine Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4OCCOC4=CC=3)C=2)C)=CC=C(F)C=C1 JSCPTIXCTAHXPN-KRWDZBQOSA-N 0.000 claims 1
- VQWGATRZKBOUBO-OAHLLOKOSA-N 4-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-amine Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(N)SC=4C=CC=3)C=2)C)=CC=C(F)C=C1 VQWGATRZKBOUBO-OAHLLOKOSA-N 0.000 claims 1
- VSTWBQIXKCRGET-GOSISDBHSA-N 4-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyisoquinoline Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=CC=CC=C4C=NC=3)C=2)C)=CC=C(F)C=C1 VSTWBQIXKCRGET-GOSISDBHSA-N 0.000 claims 1
- YISLXZGNMIKWRT-GOSISDBHSA-N 4-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoline Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=CC=CC=C4N=CC=3)C=2)C)=CC=C(F)C=C1 YISLXZGNMIKWRT-GOSISDBHSA-N 0.000 claims 1
- OMZICGNXOCDOQY-HNNXBMFYSA-N 4-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzoxazol-2-amine Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(N)OC=4C=CC=3)C=2)C)=CC=C(F)C=C1 OMZICGNXOCDOQY-HNNXBMFYSA-N 0.000 claims 1
- IELBFFUILGCNND-HNNXBMFYSA-N 4-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-dihydrobenzimidazol-2-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4NC(=O)NC=4C=CC=3)C=2)C)=CC=C(F)C=C1 IELBFFUILGCNND-HNNXBMFYSA-N 0.000 claims 1
- LEMTVSSCRWSVGK-KRWDZBQOSA-N 4-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-indole Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4C=CNC=4C=CC=3)C=2)C)=CC=C(F)C=C1 LEMTVSSCRWSVGK-KRWDZBQOSA-N 0.000 claims 1
- ZUCWINSDCRYKRC-INIZCTEOSA-N 4-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-2-methyl-1h-benzimidazole Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(C)NC=4C=CC=3)C=2)C)=CC=C(F)C=C1 ZUCWINSDCRYKRC-INIZCTEOSA-N 0.000 claims 1
- BNCRBAOIENNLQJ-OAHLLOKOSA-N 5-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,4-dihydroquinoxaline-2,3-dione Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4NC(=O)C(=O)NC=4C=CC=3)C=2)C)=CC=C(F)C=C1 BNCRBAOIENNLQJ-OAHLLOKOSA-N 0.000 claims 1
- NUKSEKWGAPTQQK-QGZVFWFLSA-N 5-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-quinolin-2-one Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4C=CC(=O)NC=4C=CC=3)C=2)C)=CC=C(F)C=C1 NUKSEKWGAPTQQK-QGZVFWFLSA-N 0.000 claims 1
- FPFOXXIEQLBLBM-QGZVFWFLSA-N 5-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4CCC(=O)NC=4C=CC=3)C=2)C)=CC=C(F)C=C1 FPFOXXIEQLBLBM-QGZVFWFLSA-N 0.000 claims 1
- LRCTWMPVWPCBNB-GOSISDBHSA-N 5-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyisoquinoline Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=CC=NC=C4C=CC=3)C=2)C)=CC=C(F)C=C1 LRCTWMPVWPCBNB-GOSISDBHSA-N 0.000 claims 1
- PFEUUKWPJVHOQZ-GOSISDBHSA-N 5-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoline Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=CC=CN=C4C=CC=3)C=2)C)=CC=C(F)C=C1 PFEUUKWPJVHOQZ-GOSISDBHSA-N 0.000 claims 1
- GNUNONSELUXVTK-HNNXBMFYSA-N 5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-amine Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4N=C(N)SC4=CC=3)C=2)C)=CC=C(F)C=C1 GNUNONSELUXVTK-HNNXBMFYSA-N 0.000 claims 1
- ONYGTRSXZBDGSI-HNNXBMFYSA-N 5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-dihydrobenzimidazol-2-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4NC(=O)NC4=CC=3)C=2)C)=CC=C(F)C=C1 ONYGTRSXZBDGSI-HNNXBMFYSA-N 0.000 claims 1
- YSXXFHNQKRMELN-INIZCTEOSA-N 5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-quinoxalin-2-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=CC(=O)NC=4C=CC=3)C=2)C)=CC=C(F)C=C1 YSXXFHNQKRMELN-INIZCTEOSA-N 0.000 claims 1
- CKIKMPRUHSOIMT-KRWDZBQOSA-N 5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-2h-isoquinolin-1-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=C(C(NC=C4)=O)C=CC=3)C=2)C)=CC=C(F)C=C1 CKIKMPRUHSOIMT-KRWDZBQOSA-N 0.000 claims 1
- XTWSEPNTKQUJQN-KRWDZBQOSA-N 5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-3,3-dimethyl-1h-indol-2-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4C(C)(C)C(=O)NC4=CC=3)C=2)C)=CC=C(F)C=C1 XTWSEPNTKQUJQN-KRWDZBQOSA-N 0.000 claims 1
- PRJLJIWJGYYOLC-QWMSRCPPSA-N 5-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-4a,8a-dihydroquinoxaline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C4N=CC=NC4C=CC=3)C=2)C)=CC=C(F)C=C1 PRJLJIWJGYYOLC-QWMSRCPPSA-N 0.000 claims 1
- UDOXWAWDKFIXTN-KRWDZBQOSA-N 6-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-indole Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4NC=CC4=CC=3)C=2)C)=CC=C(F)C=C1 UDOXWAWDKFIXTN-KRWDZBQOSA-N 0.000 claims 1
- LRYHPUQGKQRAOP-KRWDZBQOSA-N 6-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-3,4-dihydro-2h-1,4-benzoxazine Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4NCCOC4=CC=3)C=2)C)=CC=C(F)C=C1 LRYHPUQGKQRAOP-KRWDZBQOSA-N 0.000 claims 1
- MHTWWXJLMBGANA-INIZCTEOSA-N 6-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-4h-1,4-benzoxazin-3-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4NC(=O)COC4=CC=3)C=2)C)=CC=C(F)C=C1 MHTWWXJLMBGANA-INIZCTEOSA-N 0.000 claims 1
- BSOGQFMCAKIGGT-SFHVURJKSA-N 6-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyisoquinoline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4C=CN=CC4=CC=3)C=2)C)=CC=C(F)C=C1 BSOGQFMCAKIGGT-SFHVURJKSA-N 0.000 claims 1
- VBJBXWKGGSXBTF-SFHVURJKSA-N 6-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4C=CC=NC4=CC=3)C=2)C)=CC=C(F)C=C1 VBJBXWKGGSXBTF-SFHVURJKSA-N 0.000 claims 1
- DNEDVRVDBVHZFC-KRWDZBQOSA-N 7-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-indole Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4NC=CC=4C=CC=3)C=2)C)=CC=C(F)C=C1 DNEDVRVDBVHZFC-KRWDZBQOSA-N 0.000 claims 1
- LZUSMYQLRMSSDC-KRWDZBQOSA-N 7-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1h-quinolin-2-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4N=C(O)C=CC4=CC=3)C=2)C)=CC=C(F)C=C1 LZUSMYQLRMSSDC-KRWDZBQOSA-N 0.000 claims 1
- MZNVMDGLTYUMJP-SFHVURJKSA-N 7-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyisoquinoline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4C=NC=CC4=CC=3)C=2)C)=CC=C(F)C=C1 MZNVMDGLTYUMJP-SFHVURJKSA-N 0.000 claims 1
- PVIXMJZBKISHTM-SFHVURJKSA-N 7-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=C4N=CC=CC4=CC=3)C=2)C)=CC=C(F)C=C1 PVIXMJZBKISHTM-SFHVURJKSA-N 0.000 claims 1
- JWVYSXJJOZVAPL-QGZVFWFLSA-N 8-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinolin-2-amine Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=NC(N)=CC=C4C=CC=3)C=2)C)=CC=C(F)C=C1 JWVYSXJJOZVAPL-QGZVFWFLSA-N 0.000 claims 1
- KWMOWTUGDXZIRE-GOSISDBHSA-N 8-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoline Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=NC=CC=C4C=CC=3)C=2)C)=CC=C(F)C=C1 KWMOWTUGDXZIRE-GOSISDBHSA-N 0.000 claims 1
- CFQFFMPSCONHJO-MRXNPFEDSA-N 8-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoxalin-2-amine Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=NC(N)=CN=C4C=CC=3)C=2)C)=CC=C(F)C=C1 CFQFFMPSCONHJO-MRXNPFEDSA-N 0.000 claims 1
- ZLMJVRKQJANWAK-KRWDZBQOSA-N 8-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-2,4-dihydro-1h-isoquinolin-3-one Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4CNC(=O)CC=4C=CC=3)C=2)C)=CC=C(F)C=C1 ZLMJVRKQJANWAK-KRWDZBQOSA-N 0.000 claims 1
- OIRWAAAHAQGSHU-SFHVURJKSA-N 8-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyisoquinoline Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=CN=CC=C4C=CC=3)C=2)C)=CC=C(F)C=C1 OIRWAAAHAQGSHU-SFHVURJKSA-N 0.000 claims 1
- JWVYSXJJOZVAPL-KRWDZBQOSA-N 8-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinolin-2-amine Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=NC(N)=CC=C4C=CC=3)C=2)C)=CC=C(F)C=C1 JWVYSXJJOZVAPL-KRWDZBQOSA-N 0.000 claims 1
- CFQFFMPSCONHJO-INIZCTEOSA-N 8-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinoxalin-2-amine Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=NC(N)=CN=C4C=CC=3)C=2)C)=CC=C(F)C=C1 CFQFFMPSCONHJO-INIZCTEOSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- 208000001387 Causalgia Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000029162 bladder disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- ORBBVAPZTVKYHZ-IAGOWNOFSA-N n-[4-[6-[(3r)-4-[(1r)-1-(4-fluorophenyl)ethyl]-3-methylpiperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide Chemical compound C1([C@H](N2[C@@H](CN(CC2)C=2N=CN=C(OC=3C=4N=C(NC(C)=O)SC=4C=CC=3)C=2)C)C)=CC=C(F)C=C1 ORBBVAPZTVKYHZ-IAGOWNOFSA-N 0.000 claims 1
- TYBKAAJEIOBBBZ-DYESRHJHSA-N n-[4-[6-[(3r)-4-[(1r)-1-(4-fluorophenyl)propyl]-3-methylpiperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide Chemical compound C1([C@H](N2[C@@H](CN(CC2)C=2N=CN=C(OC=3C=4N=C(NC(C)=O)SC=4C=CC=3)C=2)C)CC)=CC=C(F)C=C1 TYBKAAJEIOBBBZ-DYESRHJHSA-N 0.000 claims 1
- ORBBVAPZTVKYHZ-SJORKVTESA-N n-[4-[6-[(3r)-4-[(1s)-1-(4-fluorophenyl)ethyl]-3-methylpiperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide Chemical compound C1([C@@H](N2[C@@H](CN(CC2)C=2N=CN=C(OC=3C=4N=C(NC(C)=O)SC=4C=CC=3)C=2)C)C)=CC=C(F)C=C1 ORBBVAPZTVKYHZ-SJORKVTESA-N 0.000 claims 1
- TYBKAAJEIOBBBZ-UTKZUKDTSA-N n-[4-[6-[(3r)-4-[(1s)-1-(4-fluorophenyl)propyl]-3-methylpiperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide Chemical compound C1([C@@H](N2[C@@H](CN(CC2)C=2N=CN=C(OC=3C=4N=C(NC(C)=O)SC=4C=CC=3)C=2)C)CC)=CC=C(F)C=C1 TYBKAAJEIOBBBZ-UTKZUKDTSA-N 0.000 claims 1
- QUHZTEMPQQZPNB-MRXNPFEDSA-N n-[4-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(NC(C)=O)SC=4C=CC=3)C=2)C)=CC=C(F)C=C1 QUHZTEMPQQZPNB-MRXNPFEDSA-N 0.000 claims 1
- QUHZTEMPQQZPNB-INIZCTEOSA-N n-[4-[6-[4-[(1s)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxy-1,3-benzothiazol-2-yl]acetamide Chemical compound C1([C@@H](N2CCN(CC2)C=2N=CN=C(OC=3C=4N=C(NC(C)=O)SC=4C=CC=3)C=2)C)=CC=C(F)C=C1 QUHZTEMPQQZPNB-INIZCTEOSA-N 0.000 claims 1
- LEIBNSYRNVISLF-GOSISDBHSA-N n-[8-[6-[4-[(1r)-1-(4-fluorophenyl)ethyl]piperazin-1-yl]pyrimidin-4-yl]oxyquinolin-2-yl]acetamide Chemical compound C1([C@H](N2CCN(CC2)C=2N=CN=C(OC=3C4=NC(NC(C)=O)=CC=C4C=CC=3)C=2)C)=CC=C(F)C=C1 LEIBNSYRNVISLF-GOSISDBHSA-N 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 230000009092 tissue dysfunction Effects 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 230000001457 vasomotor Effects 0.000 claims 1
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 1
- 230000009278 visceral effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54389604P | 2004-02-11 | 2004-02-11 | |
| PCT/US2005/004378 WO2005077944A1 (en) | 2004-02-11 | 2005-02-11 | Pyrimidine derivatives for use as vanilloid receptor ligands and their use in the treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007522235A JP2007522235A (ja) | 2007-08-09 |
| JP2007522235A5 true JP2007522235A5 (https=) | 2008-03-21 |
Family
ID=34860474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006553265A Withdrawn JP2007522235A (ja) | 2004-02-11 | 2005-02-11 | バニロイド受容体リガンドとしての使用のためのピリミジン誘導体及び疼痛の治療におけるそれらの使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7511044B2 (https=) |
| EP (1) | EP1720868B1 (https=) |
| JP (1) | JP2007522235A (https=) |
| KR (1) | KR100813093B1 (https=) |
| CN (1) | CN1953976A (https=) |
| AR (1) | AR049771A1 (https=) |
| AT (1) | ATE447570T1 (https=) |
| AU (1) | AU2005212517B2 (https=) |
| BR (1) | BRPI0507927A (https=) |
| CA (1) | CA2555685A1 (https=) |
| DE (1) | DE602005017468D1 (https=) |
| EA (1) | EA010265B1 (https=) |
| ES (1) | ES2333973T3 (https=) |
| IL (1) | IL177369A0 (https=) |
| MY (1) | MY139645A (https=) |
| NO (1) | NO20064055L (https=) |
| TW (1) | TWI295670B (https=) |
| WO (1) | WO2005077944A1 (https=) |
| ZA (1) | ZA200607518B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1775283A4 (en) * | 2004-07-14 | 2008-12-10 | Japan Tobacco Inc | 3-AMINOBENZAMIDE COMPOUND AND INHIBITORS OF THE ACTIVITY OF VANILLOID RECEPTOR 1 (VR1) |
| KR101042490B1 (ko) | 2004-07-15 | 2011-06-16 | 니뽄 다바코 산교 가부시키가이샤 | 축합 벤즈아미드 화합물 및 바닐로이드 수용체 1형(ｖｒ1)활성 저해제 |
| WO2006089311A1 (en) * | 2005-02-15 | 2006-08-24 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| CA2632508A1 (en) * | 2005-12-28 | 2008-06-05 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compound and inhibitor of vanilloid receptor type 1 (vr1) activity |
| US7906508B2 (en) * | 2005-12-28 | 2011-03-15 | Japan Tobacco Inc. | 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity |
| MX2010004246A (es) * | 2007-10-18 | 2010-04-30 | Novartis Ag | Inhibidores de csf-1r para el tratamiento de cancer y de enfermedades oseas. |
| US7938903B2 (en) * | 2008-03-07 | 2011-05-10 | Xerox Corporation | Nanosized particles of benzimidazolone pigments |
| US8012254B2 (en) | 2008-03-07 | 2011-09-06 | Xerox Corporation | Nanosized particles of benzimidazolone pigments |
| US8025723B2 (en) | 2008-03-07 | 2011-09-27 | Xerox Corporation | Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments |
| US7985290B2 (en) | 2008-03-07 | 2011-07-26 | Xerox Corporation | Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments |
| US7883574B2 (en) * | 2008-03-07 | 2011-02-08 | Xerox Corporation | Methods of making nanosized particles of benzimidazolone pigments |
| US7857901B2 (en) * | 2008-03-07 | 2010-12-28 | Xerox Corporation | Nonpolar liquid and solid phase change ink compositions comprising nanosized particles of benzimidazolone pigments |
| US7905954B2 (en) * | 2008-03-07 | 2011-03-15 | Xerox Corporation | Nanosized particles of benzimidazolone pigments |
| PL2285786T3 (pl) * | 2008-06-16 | 2014-01-31 | Merck Patent Gmbh | Pochodne chinoksalinodionowe |
| KR101676375B1 (ko) | 2009-04-09 | 2016-11-15 | 시므라이즈 아게 | 피부 자극-완화제로서 트랜스-텔트-부틸 사이클로헥사놀을 포함하는 조성물 |
| EP2322512B1 (en) | 2009-10-19 | 2015-10-21 | Xerox Corporation | Alkylated benzimidazolone compounds and self-assembled nanostructures generated therefrom |
| US8703988B2 (en) | 2010-06-22 | 2014-04-22 | Xerox Corporation | Self-assembled nanostructures |
| US8362270B2 (en) | 2010-05-11 | 2013-01-29 | Xerox Corporation | Self-assembled nanostructures |
| HRP20200992T1 (hr) * | 2012-05-17 | 2020-10-16 | Genentech, Inc. | Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci |
| CN103923033B (zh) * | 2013-01-14 | 2015-11-18 | 天津药物研究院 | 具有抗胃溃疡作用的哌嗪类衍生物 |
| US10537552B2 (en) | 2015-05-05 | 2020-01-21 | Carafe Drug Innovation, Llc | Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers |
| CN108863949B (zh) * | 2018-07-09 | 2021-01-15 | 湖南博隽生物医药有限公司 | 一种用于治疗慢性炎性痛的辣椒素受体拮抗剂及合成方法 |
| PY2311120A (es) * | 2022-03-01 | 2023-09-14 | Syngenta Crop Protection Ag | Compuestos herbicidas |
| CN120398870A (zh) * | 2024-01-31 | 2025-08-01 | 深圳晶蛋生物医药科技有限公司 | 一种苯并吗啉类化合物及其应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725600A (en) | 1984-07-13 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent |
| US5272167A (en) | 1986-12-10 | 1993-12-21 | Schering Corporation | Pharmaceutically active compounds |
| US5750532A (en) | 1986-12-10 | 1998-05-12 | Schering Corporation | Pharmaceutically active compounds |
| US5589477A (en) | 1990-08-31 | 1996-12-31 | Nippon Shinyaku Company, Limited | Pyrimidine derivatives and drugs |
| DK168780B1 (da) * | 1992-04-15 | 1994-06-06 | Celwave R F A S | Antennesystem samt fremgangsmåde til fremstilling heraf |
| IL118469A (en) | 1995-06-15 | 2000-08-13 | Tanabe Seiyaku Co | Naphthalene derivatives their preparation and intermediates thereof |
| KR19990028230A (ko) | 1995-06-20 | 1999-04-15 | 미리암 디. 메코너헤이 | 살절지동물성 및 살진균성 시클릭 아미드 |
| ES2100129B1 (es) | 1995-10-11 | 1998-02-16 | Medichem Sa | Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion. |
| IL126762A0 (en) | 1996-05-01 | 1999-08-17 | Lilly Co Eli | Halo-substituted protein kinase c inhibitors |
| JP2001503738A (ja) | 1996-09-23 | 2001-03-21 | シンファー ラボラトリーズ，インコーポレーティッド | システイン・プロテイナーゼ調節剤として有用な３，４―ジ置換アゼチジン―２―オン誘導体 |
| US5916887A (en) | 1996-09-23 | 1999-06-29 | National Research Council Of Canada | 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| EP0944314A1 (en) | 1996-11-26 | 1999-09-29 | E.I. Du Pont De Nemours And Company | Methyl substituted fungicides and arthropodicides |
| WO1998023155A1 (en) | 1996-11-26 | 1998-06-04 | E.I. Du Pont De Nemours And Company | Arthropodicidal and fungicidal cyclic amides |
| US5932590A (en) | 1996-12-05 | 1999-08-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6093737A (en) | 1996-12-30 | 2000-07-25 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2276081A1 (en) | 1996-12-30 | 1998-07-09 | Lekhanh O. Tran | Inhibitors of farnesyl-protein transferase |
| ES2195388T3 (es) | 1997-09-05 | 2003-12-01 | Basf Ag | Procedimiento para la obtencion de hidroxilaminas (hetero)aromaticas. |
| CA2260499A1 (en) | 1998-01-29 | 1999-07-29 | Sumitomo Pharmaceuticals Company Limited | Pharmaceutical compositions for the treatment of ischemic brain damage |
| JP2002503659A (ja) | 1998-02-13 | 2002-02-05 | アベンテイス・フアルマ・ソシエテ・アノニム | 縮合した複素環式系誘導体、それらの製造及びそれらを含有する製薬学的組成物 |
| US6306866B1 (en) | 1998-03-06 | 2001-10-23 | American Cyanamid Company | Use of aryl-substituted pyrimidines as insecticidal and acaricidal agents |
| AR014975A1 (es) | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
| WO2000010997A1 (en) | 1998-08-25 | 2000-03-02 | Ortho-Mcneil Pharmaceutical, Inc. | Pyridyl ethers and thioethers as ligands for nicotinic acetylcholine receptor and its therapeutic application |
| HRP20010603A2 (en) | 1999-02-24 | 2002-08-31 | Hoffmann La Roche | Phenyl-and pyridinyl derivatives |
| GB9907683D0 (en) | 1999-04-06 | 1999-05-26 | Synphar Lab Inc | Substituted azetidin-2-ones as cysteine protease inhibitors |
| CA2375909A1 (en) | 1999-07-19 | 2001-01-25 | Shionogi & Co., Ltd. | Tricyclic compounds bearing acyloxymethoxycarbonyl pendants |
| WO2001007401A1 (en) | 1999-07-23 | 2001-02-01 | Shionogi & Co., Ltd. | Tricyclic compounds and drug compositions containing the same |
| WO2001007032A1 (en) | 1999-07-23 | 2001-02-01 | Shionogi & Co., Ltd. | Th2 differentiation inhibitors |
| WO2001014331A2 (en) | 1999-08-24 | 2001-03-01 | Regents Of The University Of California | Non-quinoline inhibitors of malaria parasites |
| JP2003529547A (ja) | 1999-09-14 | 2003-10-07 | アボット・ラボラトリーズ | 化学シナプス伝達のコントロールに有効な３−ピロリジニルオキシ−３’−ピリジルエーテル化合物 |
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| HRP20020599A2 (en) | 2000-01-18 | 2004-08-31 | Pfizer Prod Inc | Corticotropin releasing factor antagonists |
| AU2001233044A1 (en) | 2000-01-28 | 2001-08-07 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles |
| CN1431896A (zh) | 2000-04-04 | 2003-07-23 | 盐野义制药株式会社 | 含有高脂溶性药物的油性组合物 |
| WO2001076582A1 (fr) | 2000-04-05 | 2001-10-18 | Shionogi & Co., Ltd. | Micro-emulsions huile dans eau contenant des composes tricycliques ou des preconcentres de ceux-ci |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| CN1501917A (zh) | 2000-08-30 | 2004-06-02 | 美国陶氏益农公司 | 杀虫剂用化合物、杀螨剂用化合物及其使用和制备方法 |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6613776B2 (en) | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002026712A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | Quaternary amines and related inhibitors of factor xa |
| DE60137273D1 (de) | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| WO2002050052A1 (en) | 2000-12-20 | 2002-06-27 | Syngenta Participations Ag | N-acyl aminoacetonitriles having pesticidal properties |
| EP1373257B9 (en) | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| US6790845B2 (en) | 2001-04-09 | 2004-09-14 | Bristol-Myers Squibb Pharma Company | Fused heterocyclic inhibitors of factor Xa |
| US7115635B2 (en) | 2001-04-27 | 2006-10-03 | Mitsubishi Pharma Corporation | Benzylpiperidine compound |
| IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| WO2003093242A2 (en) | 2001-10-03 | 2003-11-13 | Pharmacia Corporation | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| WO2003028729A2 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| DE60226756D1 (de) | 2001-10-04 | 2008-07-03 | Merck & Co Inc | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 |
| AU2002352663B2 (en) | 2001-11-13 | 2007-06-21 | Axys Pharmaceuticals, Inc. | Cyanoalkylamino derivatives as protease inhibitors |
| MXPA04005427A (es) | 2001-12-10 | 2005-04-19 | Amgen Inc | Ligandos de receptor vainilloide y su uso en tratamientos. |
| WO2003099284A1 (en) | 2002-05-22 | 2003-12-04 | Amgen Inc. | Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain |
| CA2491895C (en) | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| BR0313255A (pt) * | 2002-08-08 | 2005-07-12 | Amgen Inc | Composto, composição farmacêutica, uso de um composto e métodos de fabricar um medicamento e de preparar um composto |
| US7419984B2 (en) | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
| GB0226724D0 (en) | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
-
2005
- 2005-02-08 MY MYPI20050501A patent/MY139645A/en unknown
- 2005-02-11 EA EA200601426A patent/EA010265B1/ru not_active IP Right Cessation
- 2005-02-11 CA CA002555685A patent/CA2555685A1/en not_active Abandoned
- 2005-02-11 ES ES05722962T patent/ES2333973T3/es not_active Expired - Lifetime
- 2005-02-11 JP JP2006553265A patent/JP2007522235A/ja not_active Withdrawn
- 2005-02-11 BR BRPI0507927-6A patent/BRPI0507927A/pt not_active IP Right Cessation
- 2005-02-11 EP EP05722962A patent/EP1720868B1/en not_active Expired - Lifetime
- 2005-02-11 KR KR1020067018172A patent/KR100813093B1/ko not_active Expired - Fee Related
- 2005-02-11 AT AT05722962T patent/ATE447570T1/de not_active IP Right Cessation
- 2005-02-11 CN CNA200580008675XA patent/CN1953976A/zh active Pending
- 2005-02-11 US US11/056,568 patent/US7511044B2/en not_active Expired - Fee Related
- 2005-02-11 WO PCT/US2005/004378 patent/WO2005077944A1/en not_active Ceased
- 2005-02-11 AU AU2005212517A patent/AU2005212517B2/en not_active Ceased
- 2005-02-11 AR ARP050100490A patent/AR049771A1/es not_active Application Discontinuation
- 2005-02-11 DE DE602005017468T patent/DE602005017468D1/de not_active Expired - Fee Related
- 2005-02-14 TW TW094104222A patent/TWI295670B/zh active
-
2006
- 2006-08-08 IL IL177369A patent/IL177369A0/en unknown
- 2006-09-08 NO NO20064055A patent/NO20064055L/no not_active Application Discontinuation
- 2006-09-08 ZA ZA200607518A patent/ZA200607518B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007522235A5 (https=) | ||
| CN101641339B (zh) | 用于预防和治疗心血管疾病的化合物 | |
| CN1659144B (zh) | 喹啉和异喹啉衍生物、其制备方法以及作为炎症抑制剂的应用 | |
| AU2010339423C1 (en) | Therapeutic compounds and related methods of use | |
| JP5007226B2 (ja) | アリールおよびヘテロアリール置換テトラヒドロイソキノリンならびにノルエピネフリン、ドーパミン、およびセロトニンの再取り込みを遮断するためのその利用方法 | |
| JP6121658B2 (ja) | 治療用化合物、及び関連する使用の方法 | |
| JP2010523644A5 (https=) | ||
| CA2624602A1 (en) | Process for preparing 6-substituted-7-azaindoles | |
| PE20081263A1 (es) | DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ß2 ADRENERGICO | |
| US20130023532A1 (en) | Indazolyl-pyrimidines as kinase inhibitors | |
| NZ596071A (en) | Oxazole substituted indazoles as pi3-kinase inhibitors | |
| JP2008537741A5 (https=) | ||
| CN107108478B (zh) | Urat1抑制剂 | |
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| TWI295670B (en) | Vanilloid receptor ligands and their use in treatments | |
| CN1933839A (zh) | 化合物和使用方法 | |
| JP2001524116A (ja) | ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つインドール誘導体 | |
| JP2016074667A (ja) | Ｓ−ニトロソグルタチオン還元酵素阻害薬としての新規置換キノリン化合物 | |
| JP2005508313A5 (https=) | ||
| CA2840627A1 (en) | Quinazolines as therapeutic compounds and related methods of use | |
| PE20081444A1 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis | |
| JP2012524794A5 (https=) | ||
| CA2634769A1 (en) | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | |
| NZ593536A (en) | Quinoline derivatives and methods of use | |
| JP2009529496A (ja) | 誘導型一酸化窒素シンターゼ抑制剤として有用なキノロン類 |